心力衰竭患者醛固酮水平与盐皮质激素受体拮抗剂疗效的关系
本研究汇总分析DOSE、CARRESS-HF、MDR、TOPCAT等队列共1019例心力衰竭患者,评估MRA治疗前后醛固酮浓度变化与盐皮质激素受体活性及临床结局的关系。结果显示低剂量MRA显著升高醛固酮但未能充分阻断受体活性。治疗前醛固酮高者MRA改善结局,治疗前醛固酮低者MRA与结局恶化相关。
要点
- MRA使用后醛固酮中位数显著升高,但受体阻断不充分。
- 治疗前醛固酮高者MRA改善临床结局,低者结局恶化。
- MRA仍是指南推荐的心衰药物,但需进一步研究优化。
核心结论
- 低剂量MRA显著升高醛固酮浓度,但在新的较高醛固酮水平下未能充分阻断盐皮质激素受体活性。
- 治疗前醛固酮浓度高者,MRA使用与受体活性改善和临床结局改善相关。
- 治疗前醛固酮浓度低者,MRA使用与受体活性恶化和临床结局恶化相关。
研究设计与样本
- 患者水平汇总队列分析,纳入DOSE、CARRESS-HF、MDR和TOPCAT研究,共1019例有MRA暴露和血浆醛固酮浓度数据的心衰患者。
- MDR队列136例患者采用尿钠钾比定量评估盐皮质激素受体活性。
- 荟萃分析额外纳入EARLIER研究300例和EPHESUS研究453例患者。
主要发现
- 汇总队列中MRA使用与醛固酮中位数显著升高相关,MRA组310 pg/mL(IQR 180,533)对比无MRA组174 pg/mL(IQR 106,299),P < .001。
- MDR队列中醛固酮水平与受体活性相关,MRA使用状态下相关系数r = -.52,P < .001;未使用MRA时r = -.44,P < .001,交互P = .65。
- 治疗前高醛固酮患者启动MRA后受体活性改善,尿钠钾比中位变化为1.4(IQR 1.1,2.9);治疗前低醛固酮患者启动MRA后受体活性恶化,尿钠钾比中位变化为-.9(IQR -2.1,-.1),组间P < .001。
- MRA使用与临床结局的关联依赖于治疗前醛固酮浓度,交互P = .005。
关键数值与推荐
- MRA组醛固酮中位数310 pg/mL(IQR 180,533),无MRA组174 pg/mL(IQR 106,299),P < .001。
- 尿钠钾比变化:治疗前高醛固酮组中位数1.4(IQR 1.1,2.9),治疗前低醛固酮组中位数-.9(IQR -2.1,-.1),P < .001。
- 低醛固酮组MRA结局HR 1.66,95% CI 1.12-2.45,P = .01。
临床怎么用
- MRA仍为指南推荐的心衰治疗药物,具有人群水平的既定获益。
- 治疗前醛固酮浓度可能有助于识别MRA获益更大的患者亚群。
- 治疗前醛固酮浓度低者使用MRA需关注潜在不利影响,但尚不足以改变当前临床实践。
局限性
- 本研究为假设生成性分析,尚需进一步研究验证。
- 汇总分析纳入的队列和样本量受到原始研究数据可及性的限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Low-dose mineralocorticoid receptor antagonists (MRAs) are guideline-recommended heart failure (HF) therapies. However, MRAs increase aldosterone production, and the sub-saturating doses utilized may allow continued mineralocorticoid receptor (MR) stimulation. The aim of the current analysis was to understand how baseline and change in aldosterone concentrations during MRA therapy impacts MR activity and clinical outcomes. METHODS: HF cohorts with MRA exposure and plasma aldosterone concentrations available were included in patient-level, pooled cohort analyses [DOSE, CARRESS-HF, MDR, and TOPCAT (n = 1019)]. In the MDR cohort (n = 136), urine sodium to potassium ratio was utilized to quantitate MR activity. The relationship of pre-MRA aldosterone concentration, MRA use, and clinical outcomes were meta-analysed utilizing the above pooled cohorts in addition to the EARLIER (n = 300) and EPHESUS (n = 453) trials. RESULTS: MRA use was associated with significantly higher median aldosterone concentrations [MRA = 310 (interquartile range, IQR 180, 533) pg/mL vs no MRA = 174 (IQR 106, 299) pg/mL, P < .001] in the pooled cohort. In the MDR cohort, higher aldosterone was correlated with higher MR activity, with a similar relationship on MRA (r = -.52, P < .001) vs off MRA (r = -.44, P < .001, P interaction = .65), differing only in that higher aldosterone concentrations were required on MRA to achieve the same level of MR activity. In patients with high pre-MRA aldosterone, new MRA initiation reduced MR activity, but MRA initiation increased MR activity in patients with low pre-MRA aldosterone [median change in urine Na/K with high aldosterone =1.4 (IQR 1.1, 2.9) vs low aldosterone = -.9 (IQR -2.1, -.1), P < .001]. In the pooled cohort, the association between MRA use and clinical outcomes was dependent on pre-MRA aldosterone concentration (P interaction = .005). In patients with high pre-MRA aldosterone, MRA was associated with substantially improved clinical outcomes [hazard ratio (HR) .63, 95% confidence interval (CI) .42-.92, P = .02]. However, in patients with low pre-MRA aldosterone, MRA use was associated with worse clinical outcomes (HR 1.66, 95% CI 1.12-2.45, P = .01). CONCLUSIONS: Low-dose MRAs significantly increase aldosterone but inadequately block MR activity (measured by urine Na/K) at these new higher aldosterone concentrations. In patients with high pre-MRA aldosterone, MRA use is associated with improved MR activity and clinical outcomes. However, in patients with lower pre-MRA aldosterone concentrations, MRA use is associated with worsened MR activity and clinical outcomes. MRAs remain guideline-directed HF medications with established population level benefit, but these hypothesis-generating findings indicate additional research is warranted to understand if outcomes can be further improved.
引用
- Rao, Ivey-Miranda, Cox, et al. Blood aldosterone concentrations and effects of mineralocorticoid receptor antagonists in heart failure. Eur Heart J. 2026. PMID: 42301739. doi:10.1093/eurheartj/ehag440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。